Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
17
ENVB Quote, Financials, Valuation and Earnings
Last price:
$4.64
Seasonality move
:
-9.15%
Day range:
$5.04 - $5.34
52-week range:
$4.55 - $96.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
0.70x
Volume:
75.6K
Avg. volume:
1.4M
1-year change:
-91.04%
Market cap:
$2.4M
Revenue:
--
EPS (TTM):
-$81.48
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Enveric Biosciences, Inc. has 2469.59% upside to fair value with a price target of $10.00 per share.
ENVB vs. S&P 500
-
Over the past 5 trading days, Enveric Biosciences, Inc. has underperformed the S&P 500 by -12.62% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Enveric Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enveric Biosciences, Inc. revenues have been falling on a year-over-year basis for 13 quarters in a row. In the most recent quarter Enveric Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Enveric Biosciences, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Enveric Biosciences, Inc. reported earnings per share of -$10.81.
Enterprise value:
-1.3M
EV / Invested capital:
-0.39x
Price / LTM sales:
0.02x
EV / EBIT:
--
EV / Revenue:
-0.04x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$243.9K
Return On Assets:
-233%
Net Income Margin (TTM):
--
Return On Equity:
-322.21%
Return On Invested Capital:
-322.21%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$414K | -$339.7K | -$243.9K | -$84.8K | -$40.4K | |
| Operating Income | -$18.9M | -$8.8M | -$9.8M | -$2.1M | -$1.9M | |
| EBITDA | -$18.5M | -$8.5M | -$9.5M | -$2M | -$1.8M | |
| Diluted EPS | -$10.89 | -$2.56 | -$81.48 | -$0.24 | -$10.81 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.3M | $22.3M | $5.8M | $3.8M | $4.1M | |
| Total Assets | $69.8M | $30.9M | $6.6M | $4.8M | $4.4M | |
| Current Liabilities | $2.2M | $2.6M | $4.2M | $839.2K | $905.9K | |
| Total Liabilities | $14.4M | $7.3M | $4.2M | $839.2K | $905.9K | |
| Total Equity | $55.4M | $23.6M | $2.4M | $4M | $3.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.8M | -$8.2M | -$7.7M | -$927.1K | -$2.1M | |
| Cash From Investing | $5.5K | -- | -- | -- | -- | |
| Cash From Financing | -$1.2M | $7M | $8.4M | $517.7K | $3M | |
| Free Cash Flow | -$15.8M | -$8.2M | -$7.7M | -$927.1K | -$2.1M | |
ENVB
Sector
Market Cap
$2.4M
$28.1M
Price % of 52-Week High
4.85%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-206%
-1.49%
1-Year Price Total Return
-91.63%
-17.13%
Beta (5-Year)
0.223
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.30
200-day SMA
Sell
Level
$12.44
Bollinger Bands (100)
Sell
Level
5.59 - 12.19
Chaikin Money Flow
Sell
Level
-23.1M
20-day SMA
Sell
Level
$5.91
Relative Strength Index (RSI14)
Sell
Level
45.47
ADX Line
Buy
Level
20.29
Williams %R
Buy
Level
-98.6207
50-day SMA
Sell
Level
$6.51
MACD (12, 26)
Sell
Level
-0.32
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
44.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-56.5358)
Sell
CA Score
(Annual)
Level (-9.5229)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (19.0686)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, ENVB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ENVB average analyst price target in the past 3 months is $10.00.
-
Where Will Enveric Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enveric Biosciences, Inc. share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Enveric Biosciences, Inc.?
Analysts are divided on their view about Enveric Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enveric Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Enveric Biosciences, Inc.'s Price Target?
The price target for Enveric Biosciences, Inc. over the next 1-year time period is forecast to be $10.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ENVB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enveric Biosciences, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ENVB?
You can purchase shares of Enveric Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enveric Biosciences, Inc. shares.
-
What Is The Enveric Biosciences, Inc. Share Price Today?
Enveric Biosciences, Inc. was last trading at $4.64 per share. This represents the most recent stock quote for Enveric Biosciences, Inc.. Yesterday, Enveric Biosciences, Inc. closed at $5.24 per share.
-
How To Buy Enveric Biosciences, Inc. Stock Online?
In order to purchase Enveric Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ENVB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ENVB
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
0.70x
1.81x
Price / LTM sales
0.02x
1.59x
Growth Metrics
ENVB
Sector
Revenue growth
--
4.62%
Earnings growth
-4414.86%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.55
-$0.21
Profitability
ENVB
Sector
Profitability FY 2024
-$337.5K
$3.6M
Return on invested capital
-322.21%
-31.84%
Return on assets
-233%
-27.96%
Return on equity
-322.21%
-37.63%
Earnings Date
Last Earnings Date
Dec
24
Next Earnings Date
Dec
24
Estimated Next Earnings Date
Mar
25
Balance Sheet
ENVB
Sector
Total cash
$3.8M
$26.4M
Short term investments
--
$25.7M
Total assets
$3.1M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
